Business Description
RemeGen is a biopharmaceutical company based in Yantai, China, that researches, manufactures, and sells biological medicines for patients with autoimmune conditions, cancer, and eye diseases across China and the United States. Its two main approved products are Telitacicept, used to treat lupus, rheumatoid arthritis, and related conditions, and Disitamab Vedotin, a targeted therapy for several types of cancer including gastric and breast cancer. The company also has a broad pipeline of experimental treatments in clinical development, covering a range of tumor types and disease mechanisms. Founded in 2008, RemeGen continues to expand its portfolio with the goal of addressing significant unmet medical needs.
